Christopher James Gibson, M.D.
This page shows the publications co-authored by Christopher Gibson and Robert Hasserjian.
Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica. 2018 04; 103(4):626-633.
NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. Am J Hematol. 2017 Jul; 92(7):E123-E124.
Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. Blood. 2020 12 24; 136(26):3051-3055.
Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2020 03 10; 4(5):925-929.
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.